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Abstract
Objective: Bone turnover, which regulates bone mass, may exert metabolic con-
sequences, particularly on markers of glucose metabolism and adiposity. To better 
understand these relationships, we examined cross-sectional associations between 
bone turnover markers (BTMs) and metabolic traits.
Design: β-C-terminal telopeptide of type-I collagen (β-CTX), procollagen type-1 
amino-terminal propeptide (P1NP) and osteocalcin were assessed by electrochemi-
luminescence immunoassays. Metabolic traits, including lipids and glycolysis-re-
lated metabolites, were measured using nuclear magnetic resonance spectroscopy. 
Associations of BTMs with metabolic traits were assessed using Generalized Estimating 
Equation linear regression, accounting for within-family correlation, adjusting for po-
tential confounders (age, sex, height, weight, menopause, bisphosphonate and oral 
glucocorticoid use).
Patients: 198 adults with high bone mass (HBM, BMD Z-score>+3.2), mean [SD] age 
61.6 [13.7] years; 77% female.
Results: Of 23 summary metabolic traits, citrate was positively related to all BTMs: 
adjusted ββ-CTX = 0.050 (95% CI 0.024, 0.076), P = 1.71 × 10
−4, βosteocalcin = 6.54 × 10
−4 
(1.87 × 10−4, 0.001), P = .006 and βP1NP = 2.40 × 10
−4 (6.49 × 10−5, 4.14 × 10−4), 
P = .007 (β = increase in citrate (mmol/L) per 1 µg/L BTM increase). Inverse relation-
ships of β-CTX (β = −0.276 [−0.434, −0.118], P = 6.03 × 10−4) and osteocalcin (−0.004 
[−0.007, −0.001], P = .020) with triglycerides were also identified. We explored the 
generalizability of these associations in 3664 perimenopausal women (age 47.9 [4.4] 
years) from a UK family cohort. We confirmed a positive, albeit lower magnitude, 
association between β-CTX and citrate (adjusted βwomen = 0.020 [0.013, 0.026], 
P = 1.95 × 10−9) and an inverse association of similar magnitude between β-CTX and 
triglycerides (β = −0.354 [−0.471, −0.237], P = 3.03 × 10−9).
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2019 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
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1  | INTRODUC TION
Bone is increasingly recognized to play a role in regulating energy 
metabolism. Osteocalcin is a measure of osteoblast function and 
thus bone formation.1-3 Osteocalcin-deficient mice have increased 
blood glucose, reduced insulin levels and an increase in fat mass 
compared to wild-type mice.4 In human populations, osteocalcin has 
been inversely associated with fat mass and blood glucose levels.5,6
As osteocalcin is an abundant protein in the bone matrix, it can 
also be used as a marker of bone turnover, the combined process of 
bone formation and bone resorption.1,2 When resorption exceeds 
formation, age-related bone loss occurs (potentially leading to oste-
oporosis).1 In clinical practice, bone turnover is commonly measured 
by N-terminal propeptide of type 1 procollagen (P1NP, a collagen 
product of bone formation) and beta collagen type 1 cross-linked 
C-telopeptide (β-CTX, a collagen product of bone resorption); the 
latter particularly being used to monitor response to osteoporosis 
treatments.1-3 Bone turnover markers (BTMs), which reflect metab-
olism of type 1 collagen,1,2,7 may also aid identification of individuals 
at risk of fracture.1,2
We recently gained understanding of the ‘bone turnover – meta-
bolic phenotype’ by investigating a rare and extreme population with 
high bone mass (HBM). We previously found HBM to be a sporadic 
finding of generalized raised bone mineral density (BMD) on dual-en-
ergy X-ray absorptiometry (DXA) scanning, with a prevalence of 0.18% 
among a UK DXA-scanned adult population, characterized by a largely 
asymptomatic mild skeletal dysplasia.8 Compared with relatives with 
normal BMD, HBM individuals have lower bone turnover, including re-
duced osteocalcin levels, with increased fat mass in women.9
We therefore aimed to understand the relationships between 
bone turnover and metabolic markers by examining cross-sectional 
associations between BTMs and a series of metabolic traits mea-
sured using a high-throughput proton nuclear magnetic resonance 
spectroscopy (NMR) platform, in HBM individuals. We hypothesized 
that the predominant associations observed would be between 
BTMs and metabolic markers of fat metabolism. Furthermore, we 
aimed to assess the generalizability of any bone turnover-associated 
metabolic traits, by examining whether similar relationships exist 
in unselected individuals of differing age groups from the general 
population.
2  | METHODS
2.1 | High bone mass (HBM) population
The HBM study is a UK-based multicentred observational study of 
adults with unexplained HBM. At four of our larger centres, 788 
cases of unexplained HBM were identified by screening NHS dual 
X-ray absorptiometry (DXA) databases (n = 219 088 DXA images). 
Full details of DXA database screening and participant recruitment 
have previously been reported.8 In brief, HBM was defined as a) 
L1 Z-score of ≥+3.2 plus total hip Z-score of ≥+1.2 or b) total hip 
Z-score ≥+3.2 plus L1 Z-score of ≥+1.2. Cases with significant os-
teoarthritis and/or other causes of raised BMD were excluded (eg 
surgical metalwork, Paget's disease, metastases). Index cases were 
asked to pass on study invitations to their first-degree relatives 
and spouse/partner(s). Relatives/spouses with HBM were in turn 
asked to pass on study invitations to their first-degree relatives 
and spouses. First-degree relatives and spouses were recruited, in 
whom HBM status was defined as L1 Z plus total hip Z-scores of 
≥+3.2. Family controls comprised unaffected relatives and spouses 
(Figure S1). All participants (214 with HBM and 126 family con-
trols without HBM) were clinically assessed by one doctor using 
a standardized structured history and examination questionnaire, 
after which nonfasted phlebotomy was performed. Written in-
formed consent was obtained from all participants in line with the 
Declaration of Helsinki.10 Recruitment ran from July 2005 to April 
2010. Participants were excluded if they were under 18 years old, 
pregnant or unable to provide written informed consent for any 
reason. The study was approved by the Bath Multi-centre Research 
Ethics Committee (REC reference 05/Q2001/78) and at each local 
NHS REC.
2.2 | Avon longitudinal study of parents and 
children (ALSPAC)
ALSPAC is a long-standing prospective cohort study of 14 541 
pregnancies with expected delivery dates between 01/04/1991 
and 31/12/1992, in Southwest England.11,12 Of these pregnancies, 
14 676 foetuses resulted in 14 062 live births, with 13 988 children 
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Conclusions: Bone resorption is positively related to circulating citrate and inversely 
related to triglycerides. Further studies are justified to determine whether plasma 
citrate or triglyceride concentrations are altered by factors known to modulate bone 
resorption, such as bisphosphonates.
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alive at 1 year. When the oldest children were aged approximately 
7 years, an attempt was made to augment the initial sample, resulting 
in 811 additional children being enrolled. We analysed data collected 
from the mothers (first clinic session December 2008-July 2011) and 
offspring when aged 15 years (third clinic). A total of 11 264 (77.5%) 
mothers were invited, of whom 4832 attended (42.9%). A total of 
10 464 (71.2%) offspring were invited, of whom 5506 (52.6%) at-
tended (Figure S2). The study website details all available data 
through a fully searchable data dictionary: http://www.brist ol.ac.
uk/alspa c/resea rcher s/our-data/. Ethical approval was obtained 
from the ALSPAC Ethics and Law committee and the local Research 
Ethics Committees.
2.3 | Assessment of bone turnover markers
In the HBM population, nonfasted P1NP and total osteocalcin were 
measured as markers of bone formation and β-CTX was measured 
as a marker of bone resorption. In ALSPAC populations, fasted 
β-CTX concentration was measured. In all, plasma was separated 
and frozen within 4 hours to −80°C and BTM concentrations were 
measured by electrochemiluminescence immunoassays (Roche 
Diagnostics), with detection limits of 4.0, 0.6 and 0.01 µg/L for 
P1NP, osteocalcin and β-CTX, respectively. Reference ranges were 
supplied by UK Supra Regional Assay Service laboratory (refer-
ence range 0.1-0.5 µg/L for β-CTX, 20-110 µg/L for P1NP and 6.8-
32.2 µg/L for osteocalcin). All inter- and intra-assay coefficients of 
variation were <6%.
2.4 | Nuclear magnetic resonance (NMR) 
metabolic profiling
Plasma metabolic profiling was performed using a targeted high-
throughput proton NMR platform, which measures absolute con-
centrations of over 150 metabolic traits, including 14 lipoprotein 
subclasses, lipids, glycolysis-related metabolites, amino acids, ke-
tone bodies and biomarkers of fluid balance and inflammation.20,22 
The protocol has been published elsewhere.13-16 To reduce the 
number of statistical tests performed, we specifically focused 
analyses on the total measures for (nonfasted) lipids, glycerides and 
phospholipids, apolipoproteins (rather than their subfactions), in 
addition to all amino acids, ketone bodies, markers of fluid balance 
and inflammation and low molecular weight metabolites, including 
glycolysis-related metabolites. This totalled 23 measures (summa-
rized in Table S1).
2.5 | Covariates
In the HBM population, researcher-administered questionnaires 
quantified bisphosphonate and glucocorticoid use, tobacco and 
alcohol consumption, menopausal history and use of oestrogen re-
placement in women. ALSPAC offspring pubertal stage was assessed 
by Tanner line drawings,17,18 using a paper questionnaire sent to all 
participants prior to clinic attendance. ALSPAC women were asked if 
they were taking hormone replacement, and to list all current medi-
cations, from which bisphosphonate and oral glucocorticoid use was 
determined. Maternal alcohol consumption was ascertained as part 
of a postal questionnaire sent in 2010. Women were considered 
postmenopausal if they had not had a period in the last 12 months 
or if their periods had stopped due to hysterectomy, ablation/ resec-
tion, chemotherapy or other medical reasons.19 Height and weight 
were measured contemporaneous to blood sampling.
2.6 | Statistical analysis
Histograms of exposure and outcome variables were visually in-
spected to identify skewed variables. Descriptive statistics were 
summarized as mean with standard deviations (SD) (or median [inter-
quartile range, IQR] for skewed variables) and counts (percentages). 
Associations between BTMs and metabolic traits were assessed by 
multivariable linear regression, with standardized variables to allow 
comparisons between metabolic traits. Robust standard errors (SEs), 
which remain unbiased if data are skewed, and confidence intervals 
(CIs) were estimated. Repeating all analyses log-transforming out-
come variables did not alter our findings, and therefore, original 
units with robust SEs are presented.
To account for intrafamily clustering, associations between BTMs 
and metabolic traits were determined using generalized estimating 
equation (GEE) linear regression. Analyses were initially performed 
unadjusted (model 1), then adjusted for the a priori confounders age 
and sex (model 2) and finally also adjusted for additional confound-
ers height, weight, menopausal status, bisphosphonate and gluco-
corticoid use (model 3). All BTMs were then added to model 3 (model 
4). We tested for interaction between β-CTX concentration and 
HBM status using model 3. Due to the number of tests performed in 
our initial metabolite screen (23 outcomes), we adjusted our P value 
threshold of significance to account for multiple testing (α threshold 
0.05/23 = 0.002).
Analyses of ALSPAC populations also used standard multivari-
able linear regression with robust SEs. For the mother's cohort, 
model 3 was adjusted for age, height, weight, menopausal status 
and fasting time prior to sample collection (<8 or ≥8 hours). As 
only 14 mothers reported bisphosphonate use and 12 oral gluco-
corticoid use, we removed these mothers in a sensitivity analysis. 
For the offspring population, model 3 was adjusted for age, sex, 
height, weight, Tanner stage and time of sample collection (AM or 
PM). All adjusted analyses, including in the HBM population, were 
performed with the metabolic traits in their original units to allow 
comparison between populations. All analyses were performed in 
Stata version 13 (Statacorp), and figures were generated using R 
version 3.5.1.
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3  | RESULTS
3.1 | Characteristics of the HBM population
The 198 HBM individuals had mean (SD) age 62 (14) years, BMI 
30.5 (5.8) kg/m2, and 77% were female. Median (IQR) BTM concen-
trations were as follows: β-CTX 0.17 (0.12-0.25) µg/L, P1NP 32.0 
(23.0-44.0) µg/L and osteocalcin 16.6 (13.1-21.2) µg/L (Table S2).
3.2 | Unadjusted analysis of metabolic traits and 
bone turnover in individuals with HBM
Of 23 metabolic traits, plasma citrate was positively related to all 
three BTMs (ββ-CTX = 0.31 [0.15, 0.48], P = 1.89 × 10
−4, βP1NP = 0.19 
[0.03, 0.35], P = .017 and βOsteocalcin = 0.22 [0.07, 0.38], P = .006, 
β represents the SD increase in citrate per SD increase in BTM) 
(Figure 1), but only the β-CTX-citrate association met our cor-
rected P value threshold (Table 1 shows results where β represents 
the mmol/L increase in citrate per 1 µg/L increase in BTM). Mean 
(SD) citrate concentration was 0.13 (0.03) mmol/L and increased 
by quintile of β-CTX (Figure 2A). Both β-CTX and osteocalcin were 
inversely associated with triglycerides (standardized β = −0.16 
[−0.25, −0.07], P = 3.32 × 10−4, β = −0.13 [−0.23, −0.03], P = .009 
respectively), whilst P1NP was not. Nominal inverse associations 
between all three BTMs and phosphoglycerides, P1NP and cho-
lines, β-CTX and apolipoprotein B, β-CTX/ osteocalcin and glu-
cose, osteocalcin and lactate, β-CTX and alanine, with a positive 
association between β-CTX and β-hydroxybutyrate, were detected 
(0.002 < P ≤ .05).
3.3 | Adjusted analysis of metabolic traits and bone 
turnover in individuals with HBM
As citrate was most strongly related to bone turnover, it was pri-
oritized for further analysis. The associations between citrate and 
all three BTMs were unchanged by adjustment for confounders 
(Table 1). When combining all three BTMs in model 4, only β-CTX 
remained independently associated with citrate, with similar ef-
fect sizes as seen before adjustment (βmodel 1 = 0.06 [0.03, 0.08], 
P = 1.89 × 10−4 and βmodel 4 = 0.05 [0.01, 0.10], P = .019, β represents 
the unit increase in citrate in mmol/L per 1 µg/L increase in β-CTX).
β-CTX-triglyceride and osteocalcin-triglyceride associations 
were also robust to covariate adjustment (Table 1). β-CTX was in-
versely associated with all triglyceride subvariables (triglycerides in 
VLDL, LDL and HDL), particularly VLDL triglycerides (Table S3). The 
association between osteocalcin and triglycerides appeared driven 
F I G U R E  1   Unadjusted associations between bone turnover markers and metabolic traits for all individuals with HBM. Points represent 
the SD increase in metabolic trait per SD increase in bone turnover marker. Horizontal lines represent 95% confidence intervals. Results are 
presented in SD units for comparison between metabolic traits. N ranges from 186 to 198 depending on metabolite. Abbreviations: β-CTX: 
collagen type 1 cross-linked C-telopeptide; P1NP: N-terminal propeptide of type 1 procollagen. Total C: total cholesterol. [Colour figure can 
be viewed at wileyonlinelibrary.com]
     |  33HARTLEY ET AL.
by VLDL. As seen with citrate, when combining all BTMs in the same 
model, only β-CTX was independently associated with total, VLDL 
and LDL triglycerides, and osteocalcin was independently associ-
ated with HDL triglycerides (Table 1, Table S3). Triglycerides were 
not related to citrate (age- and sex-adjusted standardized β = −0.038 
[−0.191, 0.114]).
3.4 | Generalizability of the association between 
β-CTX and metabolic traits
We aimed to assess whether bone resorption is similarly associ-
ated with citrate in different populations: perimenopausal women 
with normal BMD (mean [SD] total hip T-score + 0.24 [1.6]) and 
TA B L E  1   Multivariable associations between bone turnover markers and citrate/triglycerides in individuals with HBM
N = 198 Model 1 Model 2 Model 3 Model 4
β (95% CI) P value β (95% CI) P value β (95% CI) P value β (95% CI) P value
Citrate
β-CTX 0.055 (0.026, 
0.083)
1.89 × 10−4 0.048 (0.022, 
0.075)
2.95 × 10−4 0.050 (0.024, 
0.076)
1.71 × 10−4 0.054 (0.009, 
0.098)
.019
P1NP 2.36 × 10−4 
(4.21 × 10−5, 
4.30 × 10−4)
.017 2.35 × 10−4 
(5.13 × 10−5, 
4.18 × 10−4)
.012 2.40 × 10−4 
(6.49 × 10−5, 
4.14 × 10−4)
.007 −3.60 × 10−5 
(−2.88 × 10−4, 
2.16 × 10−4)
.779
Osteocalcin 6.90 × 10−4 
(2.03 × 10−4, 
0.001)
.006 6.61 × 10−4 
(1.76 × 10−4, 
0.001)
.008 6.54 × 10−4 
(1.87 × 10−4, 
0.001)
.006 1.84 × 10−6 
(−6.98 × 10−4, 
7.01 × 10−4)
.996
Triglycerides
β-CTX −0.288 
(−0.445, 
−0.131)
3.32 × 10−4 −0.298 
(−0.465, 
−0.130)
5.03 × 10−4 −0.276 
(−0.434, 
−0.118)
6.03 × 10−4 −0.377 (−0.628, 
−0.125)
.003
P1NP −0.001 
(−0.002, 
0.001)
.327 −0.001 
(−0.002, 
0.001)
.332 −0.001 
(−0.002, 
0.001)
.277 −0.002 (−0.013, 
0.034)
.516
Osteocalcin −0.004 
(−0.007, 
−0.001)
.009 −0.004 
(−0.007, 
−0.001)
.010 −0.004 
(−0.007, 
−0.001)
.020 0.002 
(−3.27 × 10−4, 
0.004)
.104
Note: β represents the increase in citrate/triglycerides in mmol/L per 1 µg/L increase in bone turnover marker. Model 1: unadjusted; Model 2: 
adjusted for age and sex; Model 3: adjusted for age, sex, height, weight, menopause, bisphosphonate and oral glucocorticoid use; Model 4: Adjusted 
as per model 3 plus other bone turnover markers.
Abbreviations: β-CTX, collagen type 1 cross-linked C-telopeptide; P1NP, N-terminal propeptide of type 1 procollagen.
F I G U R E  2   Mean citrate concentrations by quintiles of β-CTX in the (A) high bone mass, (B) ALSPAC mothers and (C) ALSPAC offspring 
populations. β represents the increase in citrate in mmol/L per increase in β-CTX quintile from unadjusted analyses. Abbreviations: β-CTX, 
collagen type 1 cross-linked C-telopeptide
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adolescents from the ALSPAC cohorts, in whom citrate and β-CTX 
(but not P1NP or osteocalcin) had been contemporaneously meas-
ured. Of 3664 mothers with mean age 47.9 (4.4) years, 77% were 
premenopausal. Median β-CTX and mean citrate concentrations 
were 0.25 (0.18-0.35) µg/L and 0.09 (0.03) mmol/L, respectively. Of 
2492 adolescents, with mean age 15.4 (0.3) years, 53% were female. 
Median β-CTX and the mean citrate concentrations were 0.94 (0.66-
1.39) µg/L and 0.11 (0.02) mmol/L, respectively (Table S4).
Among ALSPAC mothers, a strong positive association was seen 
between β-CTX and citrate (mean citrate concentrations increased 
by quintile of β-CTX; Figure 2B), robust to confounder adjustment 
(model 3; Table 2). The magnitude of the relationship was less marked 
than that seen in the HBM population (fully adjusted βHBM = 0.050 
[0.024, 0.076] vs βmothers = 0.020 [0.013, 0.026], β = mmol/L increase 
in citrate per 1 µg/L increase in β-CTX). The association between 
β-CTX and triglycerides also replicated in ALSPAC mothers (Table 2).
In adolescents, β-CTX quintile was strongly related to citrate 
(Figure 2C). In adjusted analyses (model 3), a 1 µg/L increase in 
β-CTX was associated with a 0.022 (0.020, 0.024) mmol/L increase 
in citrate, P = 2.10 × 10−74 (Table 2). The magnitude of the associa-
tion between β-CTX and citrate in adolescents was less than that 
seen in the HBM population. Inverse associations between β-CTX 
and total, LDL and HDL triglycerides were also observed in the ado-
lescent population (Table 2), but with a much smaller effect size than 
seen in the adult populations. After full adjustment (model 3), β-CTX 
remained positively related to total, LDL and HDL triglycerides. 
Triglycerides were inversely related to citrate in both ALSPAC pop-
ulations (fully adjusted βmothers = −0.059 [−0.090, −0.028] and βad-
olescents = −0.095 [−0.135, −0.055], β represents the SD increase in 
triglycerides per SD increase in citrate). However, adjustment for 
triglycerides did not attenuate the relationship between β-CTX and 
citrate in either population.
3.5 | Associations between β-CTX and citrate by 
HBM status
Whilst strong associations were observed between β-CTX and 
citrate in all three study populations (HBM individuals, ALSPAC 
mothers, ALSPAC children), beta coefficients were greater in HBM 
individuals. To confirm that relationships between β-CTX and citrate 
are relatively strong in HBM cases, we tested for an interaction be-
tween β-CTX concentration and citrate according to HBM status, by 
combining individuals with HBM with their family controls with nor-
mal BMD (n = 122, Figure S1). These family controls were younger 
than the HBM individuals (mean 55.0 vs 61.6 years), less commonly 
female (44% vs 77%), taller (mean 171.7 vs 166.9 cm) and had lower 
BMD (mean TH-BMD Z-score 0.53 vs 3.02). Median β-CTX and mean 
citrate concentrations in the family controls were 0.20 (0.11, 0.28) 
and 0.13 (0.03) mmol/L, respectively. There was strong evidence for 
a lower age and sex-adjusted mean β-CTX concentration in HBM 
cases compared to their relatives and weak evidence for a higher 
mean citrate concentration (mean differences = −0.047 [−0.078, T
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−0.016] µg/L and 0.005 [−2.76 × 10−4, 0.010] mmol/L for β-CTX and 
citrate, respectively). After adjustment (model 3), no association was 
seen between β-CTX and citrate in these family controls; however, 
the sample size was small (n = 122) and confidence intervals wide 
(β = 0.002[−0.02, 0.03], P = .9). A likelihood ratio test confirmed a 
difference in the association between β-CTX and citrate according 
to HBM status (P = .02; Figure 3).
3.6 | Sensitivity analyses
Adjusting for alcohol and creatinine levels in all populations and 
excluding ALSPAC mothers reporting bisphosphonates or gluco-
corticoid use did not change conclusions. The association between 
β-CTX and citrate was similar in pre- and postmenopausal ALSPAC 
mothers (P for interaction = .3), and between those fasting <8 vs 
≥8 hours before sample collection (P for interaction = .8).
4  | DISCUSSION
We report a positive association between β-CTX and plasma citrate, 
and consistent but weaker associations between osteocalcin/ P1NP 
and citrate. Furthermore, β-CTX and osteocalcin both demonstrated 
inverse associations with plasma triglycerides in individuals with 
unexplained HBM, despite adjustment for a range of confounders. 
Associations between the bone resorption marker, β-CTX, and cit-
rate and total plasma triglycerides were independent of the two bone 
formation markers, osteocalcin and P1NP. This positive association 
between β-CTX and citrate was further observed in perimenopausal 
women and adolescents from the ALSPAC population-based cohort.
Citrate is synthesized in mitochondria from acetyl-CoA and ox-
aloacetate during the Krebs cycle, where most remains, regulating 
energy production.20,21 Hence, soft tissue cellular metabolism is not 
considered a major source of plasma citrate.21 Approximately 80% of 
citrate is stored in bone and 2% of bone content is citrate.22 Citrate, 
found between hydrated layers of bone mineral and which binds to 
the surface of apatite crystals, is thought to prevent formation of 
larger crystals and thereby maintain bone structural properties.23,24 
Human osteoblasts can produce citrate; it is hypothesized that ci-
trate is incorporated into bone directly from osteoblast secretion, 
and that, as bone is resorbed and both bone collagen and mineral 
are degraded, citrate is released into the circulation generating the 
major source of plasma citrate.25 This concurs with the positive re-
lationships we observed between citrate and both age and bone 
resorption and an inverse association recently identified between 
β-CTX and citrate in a smaller sample from the ALSPAC adolescent 
population.26 Due to its suggested association with bone mineral, 
we hypothesize that plasma citrate may provide information on turn-
over of bone mineral during bone resorption.
Stronger citrate-β-CTX associations in the context of HBM 
compared with individuals with normal BMD may simply reflect 
the greater quantity of bone in the HBM skeleton and therefore a 
greater source of citrate. We have previously shown that HBM indi-
viduals have increased cortical volumetric BMD measured by pQCT, 
possibly due to reduced bone turnover allowing more time for sec-
ondary mineralization.27 Alternatively, the mineral platelets may 
be structured differently in HBM, contributing to increased bone 
strength,27 which may result in citrate being released more readily 
during bone resorption.
The inverse association between β-CTX and triglycerides in the 
adult HBM and perimenopausal populations is consistent with pre-
vious findings from the European Male Ageing Study (EMAS); mean 
β-CTX concentrations were lower in male individuals with serum 
triglyceride concentrations above 150 mg/dL, independent of other 
components of the metabolic syndrome such as hyperglycaemia.28 
As we observed, increased osteocalcin has also been associated 
with reduced triglycerides in adults.28,29 The metabolic impact of 
osteocalcin has further been demonstrated in animal studies, where 
osteocalcin-deficient mice display a distinct metabolic phenotype 
with greater accumulation of fat mass and higher serum triglyceride 
levels.4 In our analyses, the inverse association between osteocalcin 
and triglycerides was not independent of β-CTX. It is important to 
note that we determined associations between total osteocalcin and 
serum triglycerides, rather than the uncarboxylated form proposed 
to be metabolically active.4 Yet, our finding that β-CTX, rather than 
osteocalcin, was independently associated with triglycerides raises 
the possibility that β-CTX influences triglycerides via a separate 
pathway from osteocalcin. As this analysis is cross-sectional, we are 
unable to determine whether increased β-CTX causes decreased 
triglyceride levels or vice versa, yet a recent analysis did not find 
F I G U R E  3   Associations between β-CTX and citrate in 
individuals with HBM and family members with normal BMD. 
NHBM = 198 and NRelatives = 122. Regression lines represent the 
unadjusted associations between β-CTX and citrate (βHBM = 0.055 
[0.026, 0.083] and βNo HBM = 0.022 [−0.003, 0.046] where β 
represents the increase in mmol/L of citrate per 1 µg/L increase 
in β-CTX. After adjusting for age, sex, height, weight, menopause, 
bisphosphonate use and oral glucocorticoid use (model 3), β-CTX 
was still associated with citrate in individuals with HBM (0.050 
[95% CI 0.024, 0.076], P = 1.71 × 10−4) but no association was seen 
in relatives with normal BMD (8.03 × 10−4 [−0.024, 0.026], P = .95)
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evidence of a causal pathway between triglycerides and BMD after 
accounting for pleiotropy, consistent with the lack of any causal ef-
fect of triglycerides on bone turnover.30
In adolescents, we observed the opposite direction of effect 
between β-CTX and triglycerides, after adjustment for covariates: 
β-CTX was positively related to triglycerides after adjustment for 
weight. One possible explanation is that during adolescence, in-
creased bone resorption likely reflects bone modelling during growth 
rather than bone remodelling, as indicated by the positive association 
between β-CTX and periosteal circumference previously reported in 
this adolescent population.31 Pubertal growth may increase both 
bone modelling and fat storage concurrently, with higher associated 
plasma triglyceride levels. Whilst in mature adults, bone remodelling 
predominates, and hence, the direction of association reverses.
4.1 | Strengths and limitations
Strengths include the unique HBM population plus the ability to 
evaluate generalizability of findings in large population-based co-
horts of perimenopausal women and adolescents. All cohorts had 
detailed phenotypic data which allowed for models to be adjusted 
for a range of potential confounders. The metabolomics platform 
used is highly reproducible and allows efficient quantification of a 
larger number of biomarkers at scale.32
Nevertheless, this cross-sectional study is unable to examine di-
rections of causality. HBM study samples had been stored at −80°C 
for up to 10 years before metabolomics analysis; however, previous 
studies suggest that long-term storage is unlikely to significantly affect 
citrate measurements.33 The effect of different storage conditions 
and freeze-thaw cycles on metabolic trait concentrations may affect 
lipids, alanine and glucose 34; reassuringly our association between 
β-CTX and plasma triglycerides replicated with a similar effect size in 
the ALSPAC maternal cohort. Citrate has established dietary sources 
which may explain the clear positive association with fasting duration. 
β-CTX is also affected by fasting time, with β-CTX levels increasing 
with fasting.35 A weaker association was observed between β-CTX 
and citrate in those ALSPAC mothers with shorter fasts. The samples 
collected from the HBM population were not collected when fasting. 
As the HBM population is predominantly female, we wanted to repli-
cate our analysis in a female population. The ALSPAC maternal cohort 
is predominantly perimenopausal compared to the HBM population 
which is mainly postmenopausal; however, as far as we are aware, the 
ALSPAC maternal population is the largest available cohort of women 
with measured β-CTX and citrate. Finally, our study provides limited 
data as to how β-CTX relates to citrate and triglycerides in adult men, 
or adults with low bone mass, in whom further analyses are required.
5  | CONCLUSIONS
We have identified that plasma citrate is positively associated with 
β-CTX in two separate adult populations. Given that citrate binds to 
apatite nanocrystals,23 we hypothesize that circulating citrate may 
reflect breakdown of bone mineral. Further studies are justified to 
explore whether plasma citrate concentration is altered by factors 
known to modulate bone resorption, such as bisphosphonates, to 
determine the direction of causality.
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